T. Rowe Price Associates’s Stemline Therapeutics, Inc. STML Stock Holding History

T. Rowe Price Associates’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-176,795	Closed	-$1.84M	–	2568
2019 Q3	$1.84M	Sell	176,795 -582,570	-77%	-$7.62M	﹤0.01%	1597
2019 Q2	$11.6M	Sell	759,365 -133,221	-15%	-$1.93M	﹤0.01%	1291
2019 Q1	$11.5M	Buy	+892,586	New	+$10.1M	﹤0.01%	1296
2014 Q4	–	Sell	-54,473	Closed	-$679K	–	2575
2014 Q3	$679K	Sell	54,473 -38,719	-42%	-$477K	﹤0.01%	1830
2014 Q2	$1.37M	Sell	93,192 -737,074	-89%	-$11.3M	﹤0.01%	1652
2014 Q1	$16.9M	Sell	830,266 -46,400	-5%	-$1.13M	﹤0.01%	1159
2013 Q4	$17.2M	Sell	876,666 -47,500	-5%	-$1.27M	﹤0.01%	1140
2013 Q3	$41.9M	Sell	924,166 -6,034	-0.6%	-$197K	0.01%	882
2013 Q2	$22.2M	Buy	+930,200	New	+$14.8M	0.01%	1041

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates's STML Position: Q4 2019 in Review

T. Rowe Price Associates sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 176,795 shares — an estimated $1.84M sold.

T. Rowe Price Associates first reported a position in STML in Q2 2013 and held it in 9 quarters. The position peaked at $41.9M in Q3 2013. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

T. Rowe Price Associates reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
T. Rowe Price Associates sold 176,795 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $1.84M.
T. Rowe Price Associates first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
T. Rowe Price Associates's Stemline Therapeutics, Inc. position peaked at $41.9M in Q3 2013.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on T. Rowe Price Associates's 13F filing for Q4 2019, filed 14 Feb 2020.